April 4, 2011
NOTE: Several fact sheets describe drugs that are being tested against HIV:
These drugs have not been approved by the Food and Drug Administration (FDA) for use against HIV.
Apricitabine (ATC, AVX754) by Avexa. A meeting with the FDA in early 2011 discussed results from Phase II/III studies. Avexa is proceeding with its development.
CMX157 by Chimerix is a version of tenofovir with better properties in the body. It has completed a Phase I trial.
Dexelvucitabine (DFC, Reverset), formerly known as Reverset, is being developed by Pharmasset. DFC is a once-daily pill. DFC has shown activity against HIV that is already resistant to several antiretroviral drugs.
DOT (Dioxolane thymidine) is being studied by the University of Georgia in Phase I trials.
Elvucitabine (ACH-126,443, Fd4C) by Achillion Pharmaceuticals is a once-daily drug with activity against HIV that is resistant to several other nukes. It is also effective against hepatitis B. It has successfully completed one year of a Phase II study.
Festinavir (E-d4T, OBP-601) by Bristol-Myers Squibb showed good results in a Phase I trial. It may be a once-daily drug.
GS7340 is a new version of tenofovir. It is a "prodrug" of tenofovir: when it is broken down in the body, it produces tenofovir. Phase Ib study results showed it is much more potent than tenofovir and may have fewer side effects.
MIV-210 (FLG) by GlaxoSmithKline and Medivir shows good activity against HIV with resistance to other nukes. It is in Phase I trials.
Racivir by Pharmasset Inc is active against HIV and hepatitis B in laboratory studies. In a Phase I/II study, Racivir showed anti HIV activity that lasted more than 2 weeks after the drug was stopped. The makers hope that Racivir can be used as a once-daily drug.